NO994902L - Forebygging av brystkreft ved selektive östrogenreseptormodulatorer - Google Patents

Forebygging av brystkreft ved selektive östrogenreseptormodulatorer

Info

Publication number
NO994902L
NO994902L NO994902A NO994902A NO994902L NO 994902 L NO994902 L NO 994902L NO 994902 A NO994902 A NO 994902A NO 994902 A NO994902 A NO 994902A NO 994902 L NO994902 L NO 994902L
Authority
NO
Norway
Prior art keywords
breast cancer
estrogen receptor
receptor modulators
selective estrogen
cancer prevention
Prior art date
Application number
NO994902A
Other languages
English (en)
Other versions
NO994902D0 (no
Inventor
Andrew Lawrence Glasebrook
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO994902D0 publication Critical patent/NO994902D0/no
Publication of NO994902L publication Critical patent/NO994902L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer en fremgangsmåte for forebygging av brystkarsinom eller kreft hos en pasient som innbefatter administrering av en terapeutisk effektiv mengde av en forbindelse som har strukturen (I) (O hvori R1 og R2 er uavhengig hydroksy eller alkoksy med en til fire karbonatomer; og R3 og R4 er uavhengig metyl eller etyl eller R3 og R4 sammen med nitrogenatomet som de er bundet til danner en pyrrolidino, metylpyrrolidino, dimetylpyrrolidino, piperidino, morfolino eller heksametylenimino ring.
NO994902A 1997-04-09 1999-10-08 Forebygging av brystkreft ved selektive östrogenreseptormodulatorer NO994902L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4311897P 1997-04-09 1997-04-09
PCT/US1998/006989 WO1998045286A1 (en) 1997-04-09 1998-04-07 Prevention of breast cancer with selective estrogen receptor modulators

Publications (2)

Publication Number Publication Date
NO994902D0 NO994902D0 (no) 1999-10-08
NO994902L true NO994902L (no) 1999-12-07

Family

ID=21925594

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994902A NO994902L (no) 1997-04-09 1999-10-08 Forebygging av brystkreft ved selektive östrogenreseptormodulatorer

Country Status (15)

Country Link
EP (1) EP0975628A4 (no)
JP (1) JP2001518897A (no)
KR (1) KR20010006215A (no)
CN (1) CN1259945A (no)
AU (1) AU6957398A (no)
CA (1) CA2286207A1 (no)
EA (1) EA199900910A1 (no)
HU (1) HUP0001845A2 (no)
ID (1) ID23653A (no)
IL (1) IL132279A0 (no)
NO (1) NO994902L (no)
PL (1) PL336206A1 (no)
TR (1) TR199903244T2 (no)
WO (1) WO1998045286A1 (no)
ZA (1) ZA982818B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
JP5558358B2 (ja) 2007-10-16 2014-07-23 レプロス セラピューティクス インコーポレイティド メタボリック症候群用のｔｒａｎｓ−クロミフェン
CA2865234A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
EP3360870A1 (en) 2013-02-19 2018-08-15 Novartis AG Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
GB201311888D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016352592B2 (en) 2015-11-10 2023-04-27 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
PE44597A1 (es) * 1995-02-28 1997-10-13 Lilly Co Eli Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
TR199903244T2 (xx) 2000-05-22
ID23653A (id) 2000-05-11
IL132279A0 (en) 2001-03-19
KR20010006215A (ko) 2001-01-26
EP0975628A4 (en) 2001-03-21
JP2001518897A (ja) 2001-10-16
EP0975628A1 (en) 2000-02-02
AU6957398A (en) 1998-10-30
CN1259945A (zh) 2000-07-12
EA199900910A1 (ru) 2000-04-24
WO1998045286A1 (en) 1998-10-15
CA2286207A1 (en) 1998-10-15
PL336206A1 (en) 2000-06-05
HUP0001845A2 (hu) 2001-06-28
NO994902D0 (no) 1999-10-08
ZA982818B (en) 1999-10-04

Similar Documents

Publication Publication Date Title
NO994901L (no) Behandling av sentralnerveforstyrrelser ved selektive östrogenreseptormodulatorer
LU93229I2 (fr) "pitolisant et ses sels pharmaceutiquement acceptables, tel que chlorhydrate"
ATE206611T1 (de) Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
HUP0001192A2 (hu) Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására
MX9800577A (es) Derivados de 4,5-diaril oxazol.
DE69516866D1 (de) Stereochemische wortmanninderivate
NO304379B1 (no) 11,21-bisfenyl-19-norpregnan-derivater, anvendelse derav og farmas°ytiske preparater inneholdende slike derivater
NZ313185A (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
ES2123546T3 (es) Uso de derivados de 1-(aminoalquil)-3-quinoxalina-2-ona para la preparacion de composiciones neuroprotectoras.
BR0011865A (pt) derivados aromáticos e heterocìclicos de fitoteróis e/ou fitostanóis para uso no tratamento e prevenção de doença cardiovascular
NO994902L (no) Forebygging av brystkreft ved selektive östrogenreseptormodulatorer
NO922380D0 (no) Substituerte 4-fenyl-4-piperidinkarboksamider med baade lokal anestetisk og analgetisk effekt samt fremgangsmaater for deres fremstilling
NO994903L (no) Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer
MX9805023A (es) Derivados de 1-metilcarbapenem.
SE8100403L (sv) Cyklohexen-derivat
PT71949B (en) Process for the preparation of new derivatives of 6,7-benzomor-phan having pharmaceutical effect
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
TR199900286A2 (xx) Pirolidin ve piperidin t�revleri.
DK1163258T3 (da) Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis
IL100955A (en) Amino-polyhydroxy- cyclopentane derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
NO975560L (no) Fremgangsmåte for å redusere bentap
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application